Advanced search
Publication Cover
OncoTargets and Therapy Volume 10, 2017 - Issue
Submit an article Journal homepage
43
Views
21
CrossRef citations to date
0
Altmetric
Case Report

Patients harboring ALK rearrangement adenocarcinoma after acquired resistance to crizotinib and transformation to small-cell lung cancer: a case report

You-cai Zhu1 Department of Chest Disease Diagnosis and Treatment Center
,
Xing-hui Liao2 Department of Tumor Molecular Laboratory, Zhejiang Rongjun Hospital, Jiaxing, Zhejiang
,
Wen-xian Wang3 Department of Chemotherapy, Zhejiang Cancer Hospital, Hangzhou, ZhejiangCorrespondence[email protected]
,
Chun-wei Xu4 Department of Pathology, Fujian Provincial Cancer HospitalCorrespondence[email protected]
,
Wu Zhuang5 Department of Medical Thoracic Oncology, Fujian Provincial Cancer Hospital, Fujian Medical University Cancer Hospital, Fujian, Fuzhou
,
Li-hua Zhong4 Department of Pathology, Fujian Provincial Cancer Hospital
,
Kai-qi Du1 Department of Chest Disease Diagnosis and Treatment Center
,
Yan-ping Chen4 Department of Pathology, Fujian Provincial Cancer Hospital
,
Gang Chen4 Department of Pathology, Fujian Provincial Cancer Hospital
&
Mei-yu Fang6 Department of Comprehensive Medical Oncology, Zhejiang Cancer Hospital, Hangzhou, Zhejiang, People’s Republic of China
 show all
Pages 3187-3192 | Published online: 27 Jun 2017

Citations (21)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Akito Fukuda & Tatsuya Yoshida. (2023) Treatment of advanced ALK-rearranged NSCLC following second-generation ALK–TKI failure. Expert Review of Anticancer Therapy 23:11, pages 1157-1167.
Read now
Alessia Spagnuolo, Paolo Maione & Cesare Gridelli. (2018) Evolution in the treatment landscape of non-small cell lung cancer with ALK gene alterations: from the first- to third-generation of ALK inhibitors. Expert Opinion on Emerging Drugs 23:3, pages 231-241.
Read now

Articles from other publishers (19)

Giuseppe Giaccone & Yongfeng He. (2023) Current knowledge of small cell lung cancer transformation from non-small cell lung cancer. Seminars in Cancer Biology 94, pages 1-10.
Crossref
Min Zhang, Ruilin Chen, Suqun Zheng & Zhen Wang. (2023) Acquired crizotinib-resistant pulmonary adenocarcinoma and subsequent primary gallbladder cancer: A case report. Medicine 102:11, pages e33162.
Crossref
Koichi Ando, Ryo Manabe, Yasunari Kishino, Sojiro Kusumoto, Toshimitsu Yamaoka, Akihiko Tanaka, Tohru Ohmori & Hironori Sagara. (2023) Comparative Efficacy of ALK Inhibitors for Treatment-Naïve ALK-Positive Advanced Non-Small Cell Lung Cancer with Central Nervous System Metastasis: A Network Meta-Analysis. International Journal of Molecular Sciences 24:3, pages 2242.
Crossref
Tomoko Shiraishi, Kei Yamasaki, Moe Kidogawa, Tatsuya Shingu, Fuki Ujimiya, Takanobu Jotatsu, Shingo Matsumoto, Hiroki Izumi, Chinatsu Nishida, Koichi Goto & Kazuhiro Yatera. (2023) Successful Treatment with Crizotinib to Overcome Drug Resistance Possibly Due to <i>Mesenchymal-epithelial Transition</i> Amplification in a Lung Cancer Patient with the <i>Echinoderm Microtubule-associated Protein-like 4-anaplastic Lymphoma Kinase</i> Fusion Gene. Internal Medicine.
Crossref
Walter Z. Wang, Alyssa Shulman, Joseph M. Amann, David P. Carbone & Philip N. Tsichlis. (2022) Small cell lung cancer: Subtypes and therapeutic implications. Seminars in Cancer Biology 86, pages 543-554.
Crossref
Xiaomeng Yin, Yueyi Li, Hang Wang, Tingting Jia, Enli Wang, Yuling Luo, Yuhao Wei, Zeyi Qin & Xuelei Ma. (2022) Small cell lung cancer transformation: From pathogenesis to treatment. Seminars in Cancer Biology 86, pages 595-606.
Crossref
Bo Xie, Ying Qiu, Juan Zhou, Dou Du, Haochuan Ma, Jiapeng Ji, Liquan Zhu & Weimin Zhang. (2022) Establishment of an acquired lorlatinib-resistant cell line of non-small cell lung cancer and its mediated resistance mechanism. Clinical and Translational Oncology 24:11, pages 2231-2240.
Crossref
Jie Huang, Shi-Ling Zhang, Chaozheng Zhou, Weiye Huang, Peng Luo, Hua-Jun Chen & Jin-Ji Yang. (2022) Genomic and Transcriptomic Analysis of Neuroendocrine Transformation in ALK-Rearranged Lung Adenocarcinoma After Treatments With Sequential ALK Inhibitors: A Brief Report. JTO Clinical and Research Reports 3:6, pages 100338.
Crossref
Fiorella Calabrese, Federica Pezzuto, Francesca Lunardi, Francesco Fortarezza, Sofia-Eleni Tzorakoleftheraki, Maria Vittoria Resi, Mariaenrica Tiné, Giulia Pasello & Paul Hofman. (2022) Morphologic-Molecular Transformation of Oncogene Addicted Non-Small Cell Lung Cancer. International Journal of Molecular Sciences 23:8, pages 4164.
Crossref
Yue Pan, Chao Deng, Zhenhua Qiu, Chenghui Cao & Fang Wu. (2021) The Resistance Mechanisms and Treatment Strategies for ALK-Rearranged Non-Small Cell Lung Cancer. Frontiers in Oncology 11.
Crossref
Yasunori Murata, Akihiro Shiroshita, Hokuto Suzuki, Kiyoshi Nakashima, Kota Takahashi, Dai Ikebe, Tsuyoshi Terashima & Masafumi Takeshita. (2021) A Case of EGFR Mutation and EML4-ALK Mutation-positive Lung Adenocarcinoma That Transformed to Small-cell Lung Cancer After Chemotherapy<i>EGFR</i>遺伝子変異，<i>ALK</i>融合遺伝子変異同時陽性例が化学療法施行後に小細胞癌転化した1症例. Haigan 61:4, pages 342-346.
Crossref
Gerald Clamon, William Zeitler, Josiah An & Taher A. Hejleh. (2020) Transformational Changes Between Non–Small Cell and Small Cell Lung Cancer—Biological and Clinical Relevance—A Review. American Journal of Clinical Oncology 43:9, pages 670-675.
Crossref
Jessica J. Lin, Adam Langenbucher, Pranav Gupta, Satoshi Yoda, Isobel J. Fetter, Marguerite Rooney, Andrew Do, Marina Kem, Kylie Prutisto Chang, Audris Y. Oh, Emily Chin, Dejan Juric, Ryan B. Corcoran, Ibiayi Dagogo-Jack, Justin F. Gainor, James R. Stone, Jochen K. Lennerz, Michael S. Lawrence, Aaron N. Hata, Mari Mino-Kenudson & Alice T. Shaw. (2020) Small cell transformation of ROS1 fusion-positive lung cancer resistant to ROS1 inhibition. npj Precision Oncology 4:1.
Crossref
Aline F. Fares, Benjamin H. Lok, Tong Zhang, Michael Cabanero, Sally C.M. Lau, Tracy Stockley, Devalben Patel, Penelope A. Bradbury, Adrian Sacher, Kazuhiro Yasufuku, Barbara A. Morash, Peter J.B. Sabatini, Lananhn N. Nguyen, Natasha B. Leighl, Ming-Sound Tsao, Frances A. Shepherd, Geoffrey Liu, Sebastiao N. Martins-Filho & Prodipto Pal. (2020) ALK-rearranged lung adenocarcinoma transformation into high-grade large cell neuroendocrine carcinoma: Clinical and molecular description of two cases. Lung Cancer 146, pages 350-354.
Crossref
Jing Hu, Yu Wang, Yuan Zhang, Yanfei Yu, Hui Chen, Kuai Liu, Ming Yao, Kai Wang, Weiguang Gu & Tao Shou. (2019) Comprehensive genomic profiling of small cell lung cancer in Chinese patients and the implications for therapeutic potential. Cancer Medicine 8:9, pages 4338-4347.
Crossref
Kiyoko Koyama, Naoko Katsurada, Naoe Jimbo, Motoko Tachihara, Daisuke Tamura, Kyosuke Nakata, Tatsuya Nagano, Masatsugu Yamamoto, Hiroshi Kamiryo, Kazuyuki Kobayashi, Tomoo Itoh & Yoshihiro Nishimura. (2019) Overexpression of CD 133 and BCL‐2 in non‐small cell lung cancer with neuroendocrine differentiation after transformation in ALK rearrangement‐positive adenocarcinoma . Pathology International 69:5, pages 294-299.
Crossref
Charbel Hobeika, Gaëlle Rached, Roland Eid, Fady Haddad, Salim Chucri, Hampig R Kourie & Joseph Kattan. (2018) ALK-rearranged adenocarcinoma transformed to small-cell lung cancer: a new entity with specific prognosis and treatment?. Personalized Medicine 15:2, pages 111-115.
Crossref
Geeta Sharma, Ines Mota, Luca Mologni, Enrico Patrucco, Carlo Gambacorti-Passerini & Roberto Chiarle. (2018) Tumor Resistance against ALK Targeted Therapy-Where It Comes From and Where It Goes. Cancers 10:3, pages 62.
Crossref
. (2017) Crizotinib. Reactions Weekly 1668:1, pages 131-131.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.